Comparison 8. Low dose CNI + mTOR‐I versus CNI.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Death	11	2750	Risk Ratio (M‐H, Random, 95% CI)	1.16 [0.71, 1.90]
1.1 Low dose CNI + immediate mTOR	9	2182	Risk Ratio (M‐H, Random, 95% CI)	1.07 [0.62, 1.87]
1.2 low dose CNI + late mTOR	2	568	Risk Ratio (M‐H, Random, 95% CI)	1.55 [0.52, 4.59]
2 Acute rejection	16	3300	Risk Ratio (M‐H, Random, 95% CI)	1.13 [0.91, 1.40]
2.1 Unspecified	3	496	Risk Ratio (M‐H, Random, 95% CI)	1.37 [0.90, 2.09]
2.2 Biopsy‐proven	13	2804	Risk Ratio (M‐H, Random, 95% CI)	1.07 [0.83, 1.37]
3 GFR	11	1749	Mean Difference (IV, Random, 95% CI)	6.24 [3.28, 9.19]
3.1 Six months	4	244	Mean Difference (IV, Random, 95% CI)	5.79 [‐3.57, 15.15]
3.2 One year	6	1293	Mean Difference (IV, Random, 95% CI)	6.63 [4.11, 9.14]
3.3 Two years	1	212	Mean Difference (IV, Random, 95% CI)	0.58 [‐3.00, 6.16]
4 Graft loss	16	3304	Risk Ratio (M‐H, Random, 95% CI)	0.67 [0.45, 1.01]
5 Serum creatinine at 1 year	6	1320	Mean Difference (IV, Random, 95% CI)	‐14.14 [‐22.55, ‐5.72]
6 Change in GFR at 2 years	1		Mean Difference (IV, Random, 95% CI)	Totals not selected
7 Adverse events	13		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
7.1 Hypertension	5	1421	Risk Ratio (M‐H, Random, 95% CI)	0.98 [0.80, 1.20]
7.2 Hyperlipidaemia	8	1793	Risk Ratio (M‐H, Random, 95% CI)	1.07 [0.89, 1.28]
7.3 CMV infection	5	1250	Risk Ratio (M‐H, Random, 95% CI)	0.41 [0.16, 1.06]
7.4 Diabetes	5	686	Risk Ratio (M‐H, Random, 95% CI)	1.36 [0.81, 2.27]
7.5 Malignancy	5	1074	Risk Ratio (M‐H, Random, 95% CI)	1.22 [0.42, 3.52]
7.6 Infection	5	1271	Risk Ratio (M‐H, Random, 95% CI)	0.95 [0.83, 1.08]
8 Subgroup analysis: graft loss	16	3304	Risk Ratio (M‐H, Random, 95% CI)	0.67 [0.45, 1.01]
8.1 Immediate mTOR	14	2736	Risk Ratio (M‐H, Random, 95% CI)	0.75 [0.48, 1.18]
8.2 Late mTOR	2	568	Risk Ratio (M‐H, Random, 95% CI)	0.40 [0.15, 1.04]
9 Subgroup analysis: GFR	11	1749	Mean Difference (IV, Random, 95% CI)	6.24 [3.28, 9.19]
9.1 Immediate mTOR	10	1537	Mean Difference (IV, Random, 95% CI)	6.91 [3.86, 9.96]
9.2 Late mTOR	1	212	Mean Difference (IV, Random, 95% CI)	0.58 [‐3.00, 6.16]
10 Subgroup analysis: acute rejection	16	3300	Risk Ratio (M‐H, Random, 95% CI)	1.13 [0.91, 1.40]
10.1 Immediate mTOR	14	2736	Risk Ratio (M‐H, Random, 95% CI)	1.09 [0.86, 1.39]
10.2 Late mTOR	2	564	Risk Ratio (M‐H, Random, 95% CI)	1.38 [0.82, 2.31]